Skip to main content

Select Drug Profiles

Pomalyst (Pomalidomide): A New Third-Generation Immunomodulatory Drug for Relapsed and/or Refractory Multiple Myeloma

Lynne Lederman, PhD, Medical Writer

Revlimid (Lenalidomide) Receives a New Indication for the Treatment of Patients with Relapsed or Progressing Mantle-Cell Lymphoma

Lisa A. Raedler, PhD, RPh

Simbrinza (Brinzolamide/Brimonidine Tartrate) Receives FDA Approval for the Treatment of Open-Angle Glaucoma or Ocular Hypertension

Simponi (Golimumab) Receives New FDA Indication as the First Subcutaneous Anti-TNF Therapy for Ulcerative Colitis

Simponi Aria (Golimumab): A New Intravenous TNF Inhibitor for the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis

Stelara (Ustekinumab) Receives New FDA Indication for the Treatment of Patients with Active Psoriatic Arthritis

Tafinlar (Dabrafenib) and Mekinist (Trametinib): Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations

Lisa A. Raedler, PhD, RPh

Tecfidera (Dimethyl Fumarate), a New Oral Therapy Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis

Xiaflex (Collagenase Clostridium Histolyticum), First Drug Approved by the FDA for Peyronie’s Disease

Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases

Lisa A. Raedler, PhD, RPh

Page 154 of 244
Results 1531 - 1540 of 2434